Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. Juli 2020 08:30 ET | Quelle: Celsion CORP

Celsion Corporation Receives Recommendation from Independent Data Monitoring Committee to Consider Stopping the Phase III OPTIMA Study

Recommendation Based on DMC’s Finding Following the Second Pre-Planned Interim Analysis that the OPTIMA Study is Unlikely to Meet its Primary Efficacy Endpoint of Overall Survival Celsion...
05. August 2019 09:00 ET | Quelle: Celsion CORP

Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III Study of ThermoDox® in Primary Liver Cancer

Independent Data Monitoring Committee to Meet in October to Evaluate Interim Trial Data LAWRENCEVILLE, N.J., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology...
17. April 2019 08:00 ET | Quelle: Celsion CORP

Celsion Corporation Announces Issuance of New Patent for ThermoDox®

Represents a Significant Advance for Celsion’s Life Cycle Management Program for ThermoDox® Establishing Bioequivalence Will Extend Market Exclusivity to 2033 LAWRENCEVILLE, N.J,...